Aflibercept biosimilar use and real-world outcomes in various retinal diseases: the AURA Korea study
Jae Ryong Song, Jehwi Jeon, Seung Chul Baek, Ashish Sharma, Min Sagong, Christopher Seungkyu Lee, Se Joon Woo, Carl Regillo, Carl Regillo, Arshad M. Khanani, David Eichenbaum, Baruch D. Kuppermann, Anat Loewenstein, Francesco Bandello, Luke Nicholson, Clara Vazquez-Alfageme, David Boyer, Nilesh Kumar, Nikulaa Parachuri, Alay Banker, Kourous A. Rezaei, Peter K. Kaiser, Frank G. Holz, Sobha Sivaprasad, Taku Wakabayashi, Giuseppe Querques, Şengül Özdek, Kodjikian Laurent, Alper Bilgic, Paolo Lanzetta, Caroline R. Baumal, Nancy Holekemp, Taiji Sakamoto, Adnan Tufail, Nicolas Yannuzzi, Giulia Corradetti, Jay Sheth, Chitaranjan Mishra, Debdulal Chakraborty, Aleksandra Rachitskaya · 2026
Read Aflibercept biosimilar use and real-world outcomes in various retinal diseases: the AURA Korea study by Jae Ryong Song, Jehwi Jeon, Seung Chul Baek, Ashish Sharma, Min Sagong, Christopher Seungkyu Lee, Se Joon Woo, Carl Regillo, Carl Regillo, Arshad M. Khanani, David Eichenbaum, Baruch D. Kuppermann, Anat Loewenstein, Francesco Bandello, Luke Nicholson, Clara Vazquez-Alfageme, David Boyer, Nilesh Kumar, Nikulaa Parachuri, Alay Banker, Kourous A. Rezaei, Peter K. Kaiser, Frank G. Holz, Sobha Sivaprasad, Taku Wakabayashi, Giuseppe Querques, Şengül Özdek, Kodjikian Laurent, Alper Bilgic, Paolo Lanzetta, Caroline R. Baumal, Nancy Holekemp, Taiji Sakamoto, Adnan Tufail, Nicolas Yannuzzi, Giulia Corradetti, Jay Sheth, Chitaranjan Mishra, Debdulal Chakraborty, Aleksandra Rachitskaya (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13518843.txt.
Description
Jae Ryong Song leads a very large team reporting the AURA Korea study in 2026 on SB15, a biosimilar copy of the eye drug aflibercept sold as Afilivu. Injections that block blood vessel growth treat several retinal diseases, and cheaper biosimilars could widen access. Real-world proof across diseases was still thin.
Records covered 1,083 eyes from 984 patients at three South Korean centers, most switching from the original drug. Retinal thickness fell by an average of 47.5 micrometers while vision held stable over about five months. Treatment-naive eyes improved more than switchers. Fluid cleared significantly in macular degeneration, vein occlusion, and diabetic swelling groups, with only one serious event noted.
Catalog record
| CREATOR | Jae Ryong Song, Jehwi Jeon, Seung Chul Baek, Ashish Sharma, Min Sagong, Christopher Seungkyu Lee, Se Joon Woo, Carl Regillo, Carl Regillo, Arshad M. Khanani, David Eichenbaum, Baruch D. Kuppermann, Anat Loewenstein, Francesco Bandello, Luke Nicholson, Clara Vazquez-Alfageme, David Boyer, Nilesh Kumar, Nikulaa Parachuri, Alay Banker, Kourous A. Rezaei, Peter K. Kaiser, Frank G. Holz, Sobha Sivaprasad, Taku Wakabayashi, Giuseppe Querques, Şengül Özdek, Kodjikian Laurent, Alper Bilgic, Paolo Lanzetta, Caroline R. Baumal, Nancy Holekemp, Taiji Sakamoto, Adnan Tufail, Nicolas Yannuzzi, Giulia Corradetti, Jay Sheth, Chitaranjan Mishra, Debdulal Chakraborty, Aleksandra Rachitskaya |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45226 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |